These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21415160)

  • 1. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
    Ritz E; Wenzel RR
    J Am Soc Nephrol; 2011 Apr; 22(4):593-5. PubMed ID: 21415160
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
    Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
    J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avosentan for overt diabetic nephropathy.
    Mann JF; Green D; Jamerson K; Ruilope LM; Kuranoff SJ; Littke T; Viberti G;
    J Am Soc Nephrol; 2010 Mar; 21(3):527-35. PubMed ID: 20167702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor blockade in patients with diabetic nephropathy.
    Rabelink TJ; Kohan DE
    Contrib Nephrol; 2011; 172():235-242. PubMed ID: 21894003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
    Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
    Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
    McCormick BB; Sydor A; Akbari A; Fergusson D; Doucette S; Knoll G
    Am J Kidney Dis; 2008 Sep; 52(3):454-63. PubMed ID: 18433957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
    Kao CC; Wu MS
    J Formos Med Assoc; 2015 Jan; 114(1):94. PubMed ID: 24974130
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renoprotective effect of monopril in patients with diabetes mellitus in the preclinical stage of diabetic nephropathy].
    Lapchyns'ka II; Zhurylo TIe; Seliuk MM; Hromova AIe
    Lik Sprava; 2002; (5-6):91-3. PubMed ID: 12442535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin antagonism and reversal of proteinuric renal disease in humans.
    Barton M
    Contrib Nephrol; 2011; 172():210-222. PubMed ID: 21894001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Slowing chronic kidney disease progression: hopes and disappointments. Vascular repair of chronic kidney].
    Boffa JJ; Chauvet S; Mihout F
    Presse Med; 2011 Nov; 40(11):1065-73. PubMed ID: 21889290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy.
    Pourshabanan P; Momeni A; Mahmoudnia L; Kheiri S
    Diabetes Metab Syndr; 2019; 13(1):132-136. PubMed ID: 30641685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R; Faraone R; Ruggenent P; Remuzzi G
    J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.